An experimental drug could help prevent Alzheimer’s disease in a particular population: study
An experimental drug has shown a promise in preventing Alzheimer’s disease for people who are at greater risk of developing illness.
According to the new study of the Washington University of St. St. Louis, where researchers were running a clinical examination of people with a rare Genetic mutations This almost “guarantees” the future Alzheimer’s development, the public statement said.
The study included 73 people in their 30s, 40s and 50s who have a mutation, which causes excessive production of amyloids in the brain.
Parkinson’s cases could be doubled globally by 2050, the study reveals
Amiloid, a brain protein and can interfere with cognitive function, is one of the characteristics of Alzheimer’s disease.
An experimental drug has shown a promise in preventing Alzheimer’s disease for people who are at greater risk of developing illness. (East)
All participants had no (or very mild) cognitive fall, they had Family history of Alzheimer’sAnd they were within 15 years ago 10 years ago after the expected age of development symptoms, the release states.
For 22 participants who have received a gantenenemab for eight years, their risk of developing symptoms has been reduced in half – from 100% to 50% – researchers reported.
“What we know is that it is possible to at least delay the beginning of the symptoms of Alzheimer’s disease and give people more years of healthy life.”
“There was no effect in those who were treated for only two to three years,” said the older author Randall J. Bateman, MD.
The findings were published in The Lancet Neurology on March 19th.
For 22 participants who have received a gantenenemab for eight years, their risk of developing symptoms has been reduced in half – from 100% to 50% – researchers reported. (East)
Gantenenerumab, a monoclonal antibody intended to target and remove amyloid plaques in the brain, is Roche in development in Switzerland and its American branch, Genentch.
Development stopped in 2023, after Roche/Genentch clinical trials He found that the drug did not satisfy his “primary endpoint” for slowing down the cognitive fall in people with an early symptomatic Alzheimer disease, the statement said.
Higher risk of dementia observed in women with a common health problem
“Everyone in this study was destined to develop Alzheimer’s disease, and some of them are not yet,” Bateman said in the edition.
“We do not yet know how long they will be left without symptoms-maybe a few years or maybe a decade. To give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amiloid antibody in the hope that they will not develop symptoms at all,” he continued.
The hope is that if the late settlements of Alzheimer had similar results, prevention methods could ultimately be available to the general population, according to researchers. (East)
“What we know is that it is possible to at least delay the beginning of the symptoms of Alzheimer’s disease and give people for many years A healthy life. “
The hope is that if the tests of Alzheimer’s late results had similar results, prevention methods could ultimately be available to the general population, Bateman said.
The risk of dementia could increase with low levels of essential vitamins
“I’m very optimistic now, because this could be the first clinical evidence of what will become prevention for people at risk of Alzheimer’s disease,” he said. “One day we may soon delay the beginning of Alzheimer’s disease for millions.”
Howard Fillit, MD, co-founder and chief scientific director at the Alzheimer’s Foundation for Drugs in New York, noted that the study first showed that early treatment was cleared to clean the plaques before the symptoms could delay the beginning of Alzheimerove- “Similarly as we treat and prevent other chronic diseases.
Although Gantenenerumab is no longer developing, researchers evaluate other anti-amyloid drugs-after a Remternetug, which made Eli Lilly-How would they determine if they could prevent Alzheimer’s disease. (East)
“We have entered the new age of Alzheimer’s research where we cannot only change the course of the disease, but also where prevention is possible with therapeutic intervention“Filllit, which was not involved in the studio, he told Fox News Digital.
Potential limitations and risks
There have been several major restrictions on research, Bateman told Fox News Digital.
The number of people was limited because of the rarity of Alzheimer’s disease caused by mutations, using external controls and the fact that the study began with lower doses, he said.
Two Alzheimer’s drug help patients live on their own at home for a long time
“Many participants are still cognitively normal and close or last -expected from the beginning, even after more than eight years of treatment, so that the effects could be greater or smaller with continuous treatment and monitoring,” Bateman remarked.
Researchers noticed that anti-amyloid drugs As it turned out that Gantenenerumab was caused by amyloid pictorial abnormalities (Aria).
Amiloid, a brain protein and can interfere with cognitive function, is one of the characteristics of Alzheimer’s disease. (East)
They appear on brain scan as “tiny stains of blood in the brain or localized Brain swelling“The statement is specified.
Most of these side effects do not cause symptoms and is not solved without treatment, but in rare cases Aria can cause serious medical problems or can even be fatal.
This latest study found that 30% of participants had Aria, probably due to higher doses of the drug.
Although two participants had to stop using Gantenerumab because of severe aria, there was no “life of dangerous harmful events and deaths,” researchers noted.
“Generally, Gantenenerumab’s safety profile in extension was similar to the one in the original examination and in other clinical trials of Gantenenerumab,” they said.
Multiple research is needed, experts agree
Dr. Chris Vercammen, an internal medicine doctor certified for a committee that specialized in Geriatry and palliative careHe said that even though these initial findings were “encouraging”, more research needed on the effects of these drugs.
“Big, randomized trials, including a variety of population and individuals with Alzheimer’s late beginning, are required to confirm these early results and determine the full potential of these treatments,” said Vercammen, who is also the medical director at Remo Health, California, for Fox News Digital. (Not included in a new study.)
Click here to get the Fox News app
“It is important to note that the design of this study focused on high risk individuals in the pre -clinical phase and therefore does not provide enough information on the impact of these drugs on Alzheimer’s later phase.”
Filllit added that this new research opens the door to further exploration of the treatment of preclinical Alzheimer’s.
Anti-amyloid drugs such as gantenenerumab have been shown to cause amyloid pictorial abnormalities (Aria), which appear on brain scan as “tiny blood stains in the brain or localized brain swelling”. (East)
“We look forward to seeing the longitudinal data as well as further studies on this approach,” he told Fox News Digital.
“These efforts bring us a step closer to our final goal Preventing diseases before he starts. “
Click here to sign up for our Health Bulletin
Although Gantenenerumab is no longer developing, researchers evaluate other anti-amyloid drugs-after a Remternetug, which made Eli Lilly-How would they determine if they could prevent Alzheimer’s disease.
“These efforts bring us a step closer to our final goal of preventing the disease before it starts.”
“These rare families with mutations may want to participate in current trials,” Bateman told Fox News Digital.
“Older general population could be interested in knowing that there were liquid tests In people with amyloid plaques to test this approach to determine whether Alzheimer’s symptoms can be prevented. “
For more health articles visit www.foxnews.com/health/health
The study was primarily funded by the Alzheimer’s Association, GHR Foundation and National Health Institutes (NIH).
Fox News Digital spoke to Roche/Genentech to comment.
